Fighting cancer with next generation armed cell and gene therapies

News & Press Releases

March 6, 2023
Regulatory Press Release
Press Release
News
Erik Penser Bank initiates coverage on Elicera Therapeutics
Read more
March 1, 2023
Regulatory Press Release
Press Release
News
Elicera Therapeutics hires Erik Penser Bank as market maker
Read more
February 17, 2023
Regulatory Press Release
Press Release
News
Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2022
Read more
All news
Immuno-oncology
Harnessing the patient’s immune system to fight cancer
Read more
Technology
A universal CAR T-cell enhancement technology platform
Read more
Pipeline
The company’s product portfolio consists of four drug candidates
Read more

Get to know Elicera Therapeutics

Elicera's strengths are based on a deep understanding of how cells and viruses can be genetically engineered to trigger a powerful immune response to cancer.

Di Yu, Head of Technical Operations and co-founder, tells more about Elicera in the film.

About Elicera

iTANK-technology platform

A universal CAR T-cell technology platform, compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.
iTANK-platform

Upcoming events and presentations

March 28, 2023
BIO-EUROPE SPRING
Read more (external link)
May 15, 2023
Aktiespararna Göteborg
Read more (external link)
May 25, 2023
Erik Penser Bank event
Read more (external link)
All Events and Presentations
Watch our latest company presentation

Sign up for Press Releases

By filling out the form you are approving that Elicera stores your information. Read more about our integrity policy here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.